Rocket Pharmaceuticals/$RCKT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Ticker
$RCKT
Sector
Primary listing
Employees
299
Headquarters
Website
RCKT Metrics
BasicAdvanced
$342M
-
-$2.24
-
-
Price and volume
Market cap
$342M
52-week high
$16.68
52-week low
$2.19
Average daily volume
2.7M
Financial strength
Current ratio
7.304
Quick ratio
7.147
Long term debt to equity
7.056
Total debt to equity
7.985
Interest coverage (TTM)
-130.71%
Profitability
EBITDA (TTM)
-236.01
Management effectiveness
Return on assets (TTM)
-40.56%
Return on equity (TTM)
-74.88%
Valuation
Price to book
1.09
Price to tangible book (TTM)
1.38
Price to free cash flow (TTM)
-1.681
Free cash flow yield (TTM)
-59.47%
Free cash flow per share (TTM)
-1.885
Growth
Earnings per share change (TTM)
-18.45%
3-year earnings per share growth (CAGR)
-9.81%
What the Analysts think about RCKT
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
RCKT Financial Performance
Revenues and expenses
RCKT Earnings Performance
Company profitability
RCKT News
AllArticlesVideos
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock
Benzinga4 weeks ago
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire4 weeks ago
Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder
Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rocket Pharmaceuticals stock?
Rocket Pharmaceuticals (RCKT) has a market cap of $342M as of November 09, 2025.
What is the P/E ratio for Rocket Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of November 09, 2025.
Does Rocket Pharmaceuticals stock pay dividends?
No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Rocket Pharmaceuticals dividend payment date?
Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) does not currently have a Beta indicator.